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 With the number of women diagnosed annually with a new 
onset of breast cancer, it is important to determine their 
overall risk factor for this development prior to their 
diagnosis.  The current research suggests that the only way to 
prevent breast cancer is by early detection with annual 
mammogram screening. 
 There is conflicting evidence out there to suggest current 
self-breast exams, as well as clinician performed breast 
exams for the detection of breast cancer, as it currently does 
not improve survival rates.  Also, mammography is the most 
“reliable means of detecting breast cancer before a mass can 
be palpated, and most slowly growing cancers can be 
identified by mammography at least 2 years before reaching 
a size detectable by palpation.”(Papadakis, et al, 2017). 
 Will the prophylactic use of metformin in high-risk women, 
decrease their overall risk of developing breast cancer? 
 Is the use of prophylactic metformin in high-risk women 
safe and effective in preventing certain types of breast 
cancer?
 As the research suggested, breast cancer is the leading cause of death between ages 40-
44 years old, yet there is conflicting recommendations on when to screen low risk 
women.  Currently, it is recommended to discuss it with women between these ages, 
and routine screening with yearly mammograms is recommended at age 45.  If there is 
a high-risk factor, these recommendations change.  
 Currently, the only tool we have to prevent breast cancer is by early detection or in 
high risk women a prophylactic double mastectomy, which a lot of women are now 
currently undergoing with a positive a BRACA gene. 
 If we could begin a medication for these high risk women prior to them having to 
undergo a double mastectomy to decrease their overall risk, this is clinically relevant 
and may prevent the complications and detrimental changes women undergo after 
surgical intervention. 
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 Breast cancer is the most common form of cancer in 
American women and is the leading cause of death 
between the ages of 40-44 years old.  
 1 in 8 women will develop breast cancer in their lifetime, 
an alarming statistic and one that is becoming more 
prevalent in our country. 
 The purpose of this research paper was to investigate 
prophylactic medication use for women who are at high 
risk for developing breast cancer, specifically evaluating 
whether the common diabetic medication Metformin is an 
effective prophylactic medication in these individuals 
prior to the onset of any type of cancer.  
 Breast cancer is one of the most common types of 
cancer in American women and is the second leading 
cause of mortality.
 In 2015, 234,190 new diagnoses were made and 40,730 
deaths from breast cancer.
 Along with a thorough history from the patient, there 
are also several risk assessment models that should be 
utilized, such as the common Gail-2 model. 
 Any women with a significant family history should 
also be educated on genetic counseling and/or testing to 
detect a BRCA1 or 2 mutation.
 Numerous individuals who are positive for this gene 
elect to undergo prophylactic treatment, such as an 
oophorectomy, mastectomy or the use of Tamoxifen, or 
an aromatase inhibitor, also called selective estrogen 
receptor modulators or SERMS.  
 These medications reduce the amount of estrogen in the 
body, have been shown to reduce cases of breast cancer, 
but also come with side effects, such as an increased 
risk of endometrial cancer, cataracts or venous 
thrombolytic events.  
 The use of metformin, specifically when women are already diagnosed with breast 
cancer, shows it’s associated with decreased levels of insulin, specifically in non-
diabetic women.  The risk of breast cancer increases in obesity, as well as increased 
insulin levels and these studies show there is potential to decrease this risk by interacting 
with the amount of insulin in the body.  
 Increased insulin like growth factors contribute to the development of certain forms of 
cancer. Epithelial cells, as well as breast cancer cells proliferate under increased insulin 
like growth factors and these growth factors were specifically associated with increased 
premenopausal breast cancers.
 After review, it was concluded that increased levels of insulin, testosterone, as well as 
estrogen increase breast cancer risk, specifically estrogen receptor or ER positive breast 
cancer, as well as recurrence rates and mortality.  
 Overall, in the studies found, there were none regarding prophylactic use of metformin 
or early use prior to the onset of breast cancer specifically for high risk patients.  
However, studies are currently in process, as well as current evidence that suggest 
patients who use metformin with type 2 diabetes have an overall decreased risk of 
developing any type of cancer.  
 Insulin growth factors or IGFs are involved in malignancy and cell 
proliferation, as well as apoptosis.  This IGF is a protein hormone that when 
stimulated by insulin, promotes synthesis and biologic activity.  
 McCance (2014) states that, “Insulin also can promote the synthesis and 
biologic availability of the male and female sex hormones, including 
estrogens, progesterone and androgens.”  Proliferation of breast cancer, as 
well as normal epithelial cells can occur due to this IGF.  High levels of 
fasting insulin were found to be associated with a two to threefold increase 
in the risk of mortality from cancer.
 Studies show an association between IGF-1 and breast cancer, not affected 
by menopausal state. 
 Pollak (2000) found that IGF’s are associated with the regulation of cell 
proliferation and positively related to common cancers, specifically 
premenopausal breast cancer.  Research has shown that individuals who have 
higher levels of IGF’s are at a higher predisposition of developing cancer 
compared to individuals who have low to normal levels of IGF’s. 
 (Ko, 2014): Looking at endometrial cancer, individuals in this study who 
were non-metformin users had worse recurrence free survival rates (95% Cl; 
p=0.02) and worsened overall survival by 2.3 times (95% Cl; p=0.005). 
 (Libby, et al., 2014): Researched new users of metformin in type II diabetics.  
They concluded that metformin users are at a lower risk overall of 
developing cancer compared to diabetics on other medications. (95% Cl; 
0.46 hazard ratio). They also concluded that once diagnosed with cancer, 
users of metformin had a decreased mortality rate of 14.9% compared to 
non-users mortality rate of 34.8%.
 (Tsilidis et al., 2014): Challenged Libby’s study by concluding that 
metformin does not affect cancer risk.  They compared two diabetic 
medications, with similar incidence of postmenopausal breast cancer (95% 
Cl; HR 1.03).  However, this trial wanted to improve their hazard ratios and 
at the end of the study they adjusted this by excluding smoking status, BMI, 
alcohol consumption, use of aspirin or NSAIDS, statins, diabetes duration 
and the year the first prescription was ordered of the diabetic medication, 
which narrowed this down to a selected population and perhaps skewed the 
results. 
 (Bodmer, 2010): Acknowledged that type II diabetes was associated with 
increased epithelial proliferation and certain types of cancer due to 
hyperinsulinemia and insulin resistance. It was concluded that short term 
users of metformin had no change in odds ratio, but comparing >30 
prescriptions, or long term use the OR adjusted to 0.63 and furthermore 
when they looked at >40 prescriptions, the OR adjusted further to 0.44, 
which concluded that long term metformin use was associated with a 
decrease incidence in breast cancer. 
 (Campagnoli, 2013): Concluded treatment with metformin has a significant 
decrease in free testosterone by 29% and estradiol by 38%, thus overall 
decreasing the risk of breast cancer, specifically ER-positive breast cancer.  
 (Niraula, 2012): Study published investigating newly diagnosed, untreated 
women in early stages of operable invasive breast cancer.  They also 
evaluated pathology reports from tumor biopsies and based these results on 
the Ki67 stain numbers which shows how quickly the tumor is proliferating, 
as well as the TUNEL methods to determine apoptosis. Results showed Ki67 
numbers or proliferation of cells decreased from 36.5 to 33.5 and the 
TUNEL method numbers increased from 0.56 to 1.05.  With this study, it 
was found that metformin has the potential to change the proliferation of 
cancer cells, based off the Ki67 and TUNEL methods. 
 (Hirsh, 2010): Found metformin may inhibit cell transformation, as well as  
inhibiting invasive growth and killing cancer stem cells.  
 (Kim, 2014): A current in process trial that is using metformin in conjunction 
with Letrozole, a hormone based chemotherapy drug.  The goal is to provide 
evidence that metformin has direct anti-tumor effects in non-diabetic ER 
positive breast cancer women.  
Factors associated with increased risk of breast cancer
Race Caucasian 
Age Older; Typically, post-menopausal 
Family history Breast cancer in parent, sibling, or child.  (higher risk if bilateral 
or premenopausal). 
Genetics BRACA1 or BRACA2 mutation
Previous medical history Endometrial cancer, Proliferative forms of fibrocystic disease, 
cancer of the other breast. 
Menstrual history Early menarche (<12 years old)
Late Menopause (>50 years old)
Reproductive history Nulliparous or late first pregnancy (>30 years old)
Table 1: Current Diagnosis and Treatment.(Papadakis; McPhee, 2017)
